Efficient algorithm for PCR testing of blood samples

ABSTRACT

A method is provided for identifying viral positive biological fluid donations in the fewest number of test cycles. The method comprises providing biological fluid donations and defining an n-dimensional matrix comprising a multiplicity of elements, each element being identified by a matrix notation comprising an index for each dimension of the array. Samples are taken from each fluid donation and mapped to a matrix element with each sample identified by its corresponding element&#39;s notation; n aliquots being taken from each sample and subpools formed from the aliquots with each subpool containing an aliquot from all samples mapped to elements in which one of the dimensional indices is fixed. Subpools are tested for viral indication and the dimensional index of each subpool that returns a positive viral indication is determined. The dimensional indices are combined to identify a subset of matrix elements that contain a viral positive sample.

CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a divisional of patent application Ser. No.10/442,780, filed May 20, 2003 now abandoned which is a divisional ofpatent application Ser. No. 09/549,477, filed Apr. 14, 2000, now U.S.Pat. No. 6,566,052, which is a divisional of patent application Ser. No.09/081,926, filed May 20, 1998, now U.S. Pat. No. 6,063,563, which is adivisional of patent application Ser. No. 08/778,610, filed Jan. 6,1997, now U.S. Pat. No. 5,780,222; which is a continuation-in-part ofpatent application Ser. No. 08/683,784, filed Jul. 16, 1996, now U.S.Pat. No. 5,834,660; which is a divisional of patent application Ser. No.08/419,620, filed Apr. 10, 1995, now U.S. Pat. No. 5,591,573.

FIELD OF THE INVENTION

The present invention relates generally to systems and processes forpreparing and analyzing samples taken from plasma donations to uniquelyidentify donations which are virus contaminated. In particular, theinvention relates to an apparatus and process for forming individual,separately sealed, and connected containers holding samples of the sameplasma as is contained in the donation. The invention also relates to anapparatus and process for forming initial screening test pools from thecontainers and testing the pools for the presence of a virus inaccordance with an algorithm to identify individual contaminateddonations in the fewest number of testing cycles.

BACKGROUND OF INVENTION

Blood, plasma, and biological fluid donation programs are essentialfirst steps in the manufacture of pharmaceutical and blood products thatimprove the quality of life and that are used to save lives in a varietyof traumatic situations. Such products are used for the treatment ofimmunologic disorders, for the treatment of hemophilia, and are alsoused in maintaining and restoring blood volume in surgical proceduresand other treat protocols. The therapeutic uses of blood, plasma, andbiological fluids require that donations of these materials be as freeas possible from viral contamination. Typically, a serology test samplefrom each individual blood, plasma, or other fluid donation is testedfor various antibodies, which are elicited in response to specificviruses, such as hepatitis C (HCV) and two forms of the humanimmunodeficiency virus (HIV-1 and HIV-2). In addition, the serology testsample may be tested for antigens designated for specific viruses suchas hepatitis B (HBV), as well as antibodies elicited in response to suchviruses. If the sample is serology positive for the presence of eitherspecific antibodies or antigens, the donation is excluded from furtheruse.

Whereas an antigen test for certain viruses, such as hepatitis B, isthought to be closely correlated with infectivity, antibody tests arenot. It has long been known that a blood plasma donor may, in fact, beinfected with a virus while testing serology negative for antibodiesrelated to that virus. For example, a window exists between the timethat a donor may become infected with a virus and the appearance ofantibodies, elicited in response to that virus, in the donor's system.The time period between the first occurrence of a virus in the blood andthe presence of detectable antibodies elicited in response to that virusis known as the “window period.” In the case of HIV, the average windowperiod is approximately 22 days, while for HCV, the average windowperiod has been estimated at approximately 98 days. Therefore, testsdirected to the detection of antibodies, may give a false indication foran infected donor if performed during the window period, i.e., theperiod between viral infection and the production of antibodies.Moreover, even though conventional testing for HBV includes tests forboth antibodies and antigens, testing by more sensitive methods haveconfirmed the presence of the HBV virus in samples which were negativein the HBV antigen test.

One method of testing donations, which have passed available antibodyand antigen tests, in order to further ensure their freedom fromincipient viral contamination, involves testing the donations by apolymerase chain reaction (PCR) method. PCR is a highly sensitive methodfor detecting the presence of specific DNA or RNA sequences related to avirus of interest in a biological material by amplifying the viralgenome. Because the PCR test is directed to detecting the presence of anessential component of the virus itself its presence in a donor may befound almost immediately after infection. There is, theoreticallytherefore, no window period during which a test may give a falseindication of freedom of infectivity. A suitable description of themethodology and practical application of PCR testing is contained inU.S. Pat. No. 5,176,995, the disclosure of which is expresslyincorporated herein by reference.

PCR testing is, however, very expensive and since the general donorpopulation includes a relatively small number of PCR positive donors,individual testing of each donation is not cost effective oreconomically feasible. Hence, an efficient and cost-effective method oftesting large numbers of blood or plasma donations to eliminate unitshaving a viral contamination above a pre-determined level is required.

One method of testing a large number of plasma donations is to pool anumber of individual plasma donations. The pool is then PCR tested andthe individual donations comprising the pool are either retained ordisposed of, depending on the outcome of the PCR test. While reducingthe number of PCR tests, and the costs associated therewith, this methodresults in a substantial waste of a significant portion of virus freedonations. Since only a single donation with a viral contamination abovea pre-determined level will cause a pool to test PCR positive, theremaining donations that contribute to a pool may well be individuallyPCR negative. This result is highly probable given that a relativelysmall number of PCR positive donors exist in the general donorpopulation. In the conventional pooling approach, all donationscomprising the pool are disposed of upon a PCR positive result,including those donations that are individually PCR negative.

In addition, plasma donations are often frozen soon after they arereceived. When samples of individual plasma donations are needed forpooling, each donation must be thawed, an aliquot of the blood or plasmaremoved from the donation, and the donation must then be refrozen forpreservation. Multiple freeze-thaw cycles may adversely affect therecovery of the RNA or DNA of interest as well as the proteins containedwithin the plasma, thus adversely affecting the integrity of the PCRtest. Moreover, each time an aliquot of individual plasma donations iswithdrawn to form a pool, the donation is subject to contamination, bothfrom the surrounding environment, and from the apparatus used towithdraw the aliquot. Further, if the donation contains a virus, it cancontaminate other donations. In order to avoid introducing viralcontaminants into an otherwise viral free donation, the sample takingapparatus must be either sterilized after each individual use, or usedfor taking only a single aliquot from a single individual donation and anew sample taking apparatus used for taking an aliquot from a subsequentindividual donation. Either of these methods involves considerableexpense and is quite time consuming.

Accordingly, there is a need for a process and system for obtainingmultiple blood or plasma samples from individual donations such thatparticular samples may be pooled without contaminating the remainingsamples. It is also desirable that the process and system is able toform such pools in a fast and efficient manner, without contaminatingeither a clinical testing lab technician or the testing laboratoryenvironment.

In addition, it is desirable that the process and system provide forefficient and cost-effective testing of the blood or plasma donations toidentify only uniquely PCR positive donations in the fewest possiblenumber of testing cycles.

SUMMARY OF INVENTION

There is, therefore, provided in the practice of this invention acost-effective and efficient process for preparing and testing samplesfrom a multiplicity of blood or plasma donations to uniquely identifydonations which are infected with virus as well as systems and devicesfor practicing the process.

The process of the present invention results in blood and plasmaproducts being substantially safer because one can readily test forvirus contamination in the blood or plasma supply directly.Cost-effective, high-sensitivity testing can be performed immediately,and contaminated donations identified, without regard to an infectivitywindow period.

In one embodiment of practice of the present invention, the processcomprises the steps of providing a blood or plasma donation in acollection container. A flexible collection segment is connected to thecontainer and is open to the inside of the container. The collectionsegment is filled with blood or plasma from the collection container,and a portion of the collection segment is sealed at both ends. Thesealed portion of the collection segment is removed from the containerand, either before or after the sealed collection segment portion isremoved, a plurality of spaced-apart seals are provided at intervalsalong the length of the collection segment between the sealed ends. Thesegment portions in the intervals between adjacent seals definecontainers, wherein each such container contains a plasma or bloodsample, and wherein the intervals between the seals provide a sufficientvolume in each such container for the planned testing.

In a more detailed embodiment of the present invention, individualplasma donations are collected in a plasma collection bottle which has atesting container connected thereto by a flexible hollow tubing segment.After being filled with a donor's plasma the plasma bottle is tipped soas to transfer plasma to the testing container and the flexible tubingsegment, thereby filling the tubing segment. The tubing segment issealed at spaced-apart intervals along its length, the tubing segmentportions in the intervals between the seals define pouches each of whichcontains a sample of the plasma donation. The tubing segment, which hasbeen converted into a series of pouches, is then disconnected from theplasma collection bottle and frozen until needed for testing.

In an additional aspect of the present invention, the hollow tubingsegment comprises a series of linked-together Y-sites, including aninjection site provided on one leg of the Y, and where each branch legof a particular Y-site which does not include an injection site isconnected to the base of the next Y-site in the chain by a flexibleplastic tubing segment. Spaced-apart heat seals are formed along thelength of each flexible plastic tubing segment separating the Y-sites.

In a further aspect of the present invention a device for providingmultiple heat seals along the length of the tubing segment filled withthe blood or plasma donation comprises first and second opposed sealplatens. Each seal platen includes a plurality of spaced-apart raisedportions along its length alternating with recessed portions. The raisedand recessed portions on the first platen are in registry withcorresponding raised and recessed portions on the second platen. Theopposed seal platens are moved together onto a plastic tubing segmentfilled with the blood or plasma donation to form heat seals on thoseportions of the tubing segment compressed between the raised portionsand to form chambers defined by opposed recessed portions. The heatseals define a plurality of individual and sequential pouchestherebetween and each chamber, defined by each closed pair of recessedportions, is configured to house a pouch.

In particular, a device for providing multiple heat seals along thelength of the tubing segment filled with a blood or plasma donation isconfigured to be mounted on a commercially available heat sealapparatus, as an after-market modification.

In yet a further embodiment of the invention, a system for collectingand preparing plasma samples for testing comprises a plasma collectioncontainer and a hollow plastic tube connected to the container, each ofwhich are constructed of plastic and each of which contain a codedindicia molded into the plastic. The coded indicia is disposed along themajor axis of the tubing segment and the code repeats at spaced-apartintervals so that the tubing segment can be provided with a plurality ofspaced apart seals along its length to thereby define pouches betweenthe seals. The code intervals of the indicia correspond to the intervalsof the pouches, so that each pouch will contain at least one cycle ofthe code.

To begin the testing process of the present invention, a first pouch isremoved from each of a group of tubing segments corresponding to aplurality of separate plasma donations. A portion of the contents ofeach such first pouch is withdrawn and the contents formed into a poolin a container.

In an exemplary embodiment of the present invention, the first pool istested for a viral indication. When the first pool tests positive for aviral indication, a next, or second, sequential pouch is removed fromeach of the tubing segments that were used to form the first pool. Thesecond pouches are divided into two approximately equal subgroups, andthe contents of one of the subgroup pools is tested for the presence ofa specific virus. When the tested subgroup pool tests negative for thevirus, a further sequential pouch is removed from corresponding tubingsegments used to form the untested subgroup. The pouches are dividedinto two approximately equal next generation subgroups, and the contentsof the subgroup pouches are formed into pools. One of the nextgeneration subgroup pools is tested for a viral indication.

When the tested subgroup pool tests positive for such viral indication,a pouch is removed from corresponding tubing segments used to form thetested subgroup. The process is iterated, with each positive pool beingfurther subdivided into successively smaller subgroups, with each of thesuccessive subgroups comprising a fraction of the samples of thepreceding positive subgroup, until the final pouch corresponding to asingle plasma donation is identified.

In a further embodiment of the present invention, an additional processfor testing a multiplicity of plasma donations to uniquely identifydonations having a positive viral indication in a single PCR testingcycle includes the steps of defining an n-dimensional grid which definesinternal elements at the intersections of each of the n-dimensions ofthe grid. A sample from each of a number of plasma donations is mappedto a corresponding element of the grid, with each sample being definedby a matrix notation, X_(res), where the subscript of the matrix elementnotation defines dimensional indices of the grid. Aliquots are takenfrom each sample of each of the plasma donations and formed intosubpools. Each subpool includes an aliquot of all plasma donationsamples in which one of the dimensional indices is fixed. The subpoolsare all tested at once, in a single PCR testing cycle, and thedimensional indicia of each subpool which tests positive is evaluated inaccordance with a reduction by the method of minors, therebyunambiguously identifying a unique element defined by the dimensionalindicia of each positive subpool, and thus unambiguously identifying auniquely positive sample.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the presentinvention will be more fully understood when considered with respect tothe following detailed description, appended claims, and accompanyingdrawings, wherein:

FIG. 1 is a semi-schematic perspective view of one example of a plasmadonation bottle and sample container attached by a tubing segment usefulin the practice of the present invention;

FIG. 2 is a semi-schematic perspective view of a tubing segmentconnected between a plasma donation bottle and sample container anddivided into pouches in accordance with the present invention;

FIG. 2 a is a semi-schematic perspective view of a tubing segmentconnected between a plasma donation bottle and sample container andincluding a series of linked-together Y-sites in accordance with thepresent invention;

FIG. 3 a is an enlarged top plan view of a portion of the tubing segmentshown in FIG. 2 showing additional details of the seals which separatethe pouches;

FIG. 3 b is a semi-schematic cross-sectional view of a tubing segmentseal;

FIG. 4 is a semi-schematic perspective view of a device provided inaccordance with practice of the present invention for sealing a tubinginto individual pouches;

FIG. 4 a is a semi-schematic perspective view of a top and bottomplatens of a heat sealing device provided in accordance with practice ofthe present invention for mounting onto a commercially available heatsealer;

FIG. 5 is a semi-schematic perspective view of a sampling plate andcover provided in accordance with the present invention;

FIG. 6 is a semi-schematic partial cross-sectional view of a plasmapouch contained in a sampling plate sample well provided in accordancewith the present invention;

FIG. 7 is a semi-schematic perspective view of a device provided inaccordance with the present invention for crushing sample pouches andexpressing the fluid samples container therein into a pool;

FIG. 8 is a semi-schematic cross-sectional view of a crushing cylinderof the device of FIG. 7;

FIG. 9 a is a semi-schematic partial cross-sectional view of a screenplate against which sample-containing packets are crushed;

FIG. 9 b is a semi-schematic top view of a screen plate showing radialand concenthc fluid gutters for collecting sample fluid from crushedsample containers;

FIG. 10 is a semi-schematic partial cross-sectional view of a crushingpiston of the device of FIG. 7;

FIG. 11 is a flow chart depicting the test methodology according to theinvention for determining PCR positive donors from a donation pool;

FIG. 12 is a flow chart depicting a test sequence according to theinvention for identifying a single PCR positive donation from a 512donation pool;

FIG. 13 is a flow chart depicting a second test methodology according tothe invention for determining PCR positive donors from a donation pool;and

FIG. 14 is a representation of a 3-dimensional grid according to theinvention showing the definition of r, c, and s indices.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to systems, processes and devices usefulfor testing blood or plasma donations to detect those specific donationswhich have a viral contamination above a pre-determined level. Suchcontaminated donations are then disposed of to thereby prevent theirincorporation into the raw material stream for pharmaceutical productsor their transfusion into human patients. The viral detection tests usedin accordance with practice of the present invention can be any thatdirectly detect a virus instead of antibodies elicited in response tothe virus. The tests include polymerase chain reaction (PCR) tests andother tests which are sufficiently sensitive to directly detect a viruseven after pooling samples from multiple donations.

In one embodiment of practice of the present invention, a plurality ofseparate blood or plasma donations are provided. A blood or plasmasample is drawn from each donation into a corresponding flexible, hollowtubing segment. A plurality of spaced-apart seals are provided atintervals along the length of the tubing segment, so that segmentportions in the intervals between seals define pouches where each pouchcontains a blood or plasma sample. As is discussed below in greaterdetail, a unique methodology is provided in accordance with the presentinvention for testing plasma samples from the pouches after the samplesare formed into pools to thereby efficiently and effectively detect andisolate any such blood or plasma donation which is contaminated withvirus.

Turning to FIG. 1, an exemplary embodiment of a system provided inaccordance with practice of the present invention for effecting thesampling process is shown. The system includes a standard plasmadonation container 20, constructed of a nonreactive material such aspolyvinyl chloride (PVC). The donation container 20 includes a cap 22having two hollow elbow shaped fittings 23 and 24, respectively,attached to the top surface thereof The fittings communicate with theinterior of the donation bottle through orifices provided in cap 22 forsuch purpose. A flexible hollow filler tube 26, constructed of abiologically neutral material, such as PVC plastic, is connected at oneend to the elbow fitting 23 and connected at the other end to, forexample, a needle which is inserted into a donor in order to procure adonation. In the illustrated embodiment, a test container 28, is alsoprovided, for collecting a sample from the donation to be serologytested. The test container 28 is generally test tube shaped and is alsoconstructed of a biologically nonreactive material. The test container28 includes an integral cap member 30 through which orifices areprovided in order to communicate with the interior of the testcontainer.

A flexible hollow tubing segment 32, constructed of a biologicallynonreactive plastic material, is connected between the cap member 30 ofthe test container 28 and the hollow elbow fitting 24 of the plasmadonation container cap. The tubing segment 32 is connected to the capmember 30 in a manner such that fluid passing through the tubing segmentwill enter the test container 28 through an orifice provided in the capmember 30 for such purpose. The tubing segment 32 may be friction fitinto said orifice, sonically welded thereto, or otherwise attached in acoaxial relationship with the orifice by techniques well understood bythose skilled in the art.

A second orifice may also be provided in the cap member 30, to which avent tube 34 is connected in a manner similar to tubing segment 32. Thevent tube is typically no more than one to two inches in length, and istypically terminated with an inserted, friction fit bacteria excludingfilter 36.

In an exemplary embodiment, a blood or plasma donation is withdrawn froma donor and collected in the plasma donation container 20 for subsequentstorage until needed. In the case of a plasma donation, blood istypically withdrawn from a donor and passed through a continuouscentrifuge apparatus, wherein red blood cells are centrifuged out fromthe supporting plasma fluid and returned to the donor. The plasma isthen collected.

After a plasma donation is taken from a donor and the donation container20 is filled, the donation container is tilted so as to raise the fluidlevel over the elbow fitting 24 connected to the tubing segment 32.Plasma enters the tubing segment, flows through the tubing segment, andfills the test container 28. During filling, air trapped within testcontainer 28 escapes through the vent tube 34, allowing the testcontainer to be filled completely. The bacteria excluding filter 36filters out any bacteria in the returning air, thus preventingcontamination of the sample by the surrounding environment. After thetest container is filled, plasma from the donation is allowed to fillthe tubing segment 32.

Turning now to FIG. 2, after the plasma sample from the donation isdrawn into the tubing segment 32, the tubing segment is sealed by a heatweld 38 or other suitable sealing means such as a sonic weld, at alocation proximate to the tubing segment's connection to the plasmadonation container. A further heat seal 40 is applied to the tubingsegment at a location proximate to the segment's connection to the testcontainer 28. An elongated hollow tube, closed off at both ends, andcontaining a quantity of the plasma donation is thus provided.

The filled portion of the tubing segment 32 is removed from the plasmadonation and test containers by cutting the tubing segment away throughthe center of the seals, 38 and 40. The separate plasma donationcontainer is then removed for freezing and storage, while the separatedtest container is removed to a laboratory for serology testing.Typically, the contents are tested for various antibodies, which areelicited in response to specific viruses, such as hepatitis C (HCV), orHIV-1 and HIV-2.

Additional seals 42 are also provided at spaced-apart intervals alongthe length of the tubing segment, to define sequential individual andconnected pouches, each suitably comprising a hollow tubing segmentportion 44. Each such portion 44 contains a particular quantity of bloodor plasma needed for the specific generation pool to be formed. Forexample, for pouches to be formed for PCR testing, approximately 0.02 to0.5 ml of blood or plasma from the host donation may be sealed.

The tubing segment is sealed in a manner to provide from 5 to 15,individual and connected pouches. Sealing, to define the pouches, may bedone either after the tubing segment has been removed from between theplasma donation container and the serology test container or preferablyis done while the tubing segment is still attached to the plasmadonation container, in order to avoid hydrostatic pressure build-up.Sealing may be done by any known method, such as thermo-compressionsealing (heat sealing), sonic welding or the like, so long as the lengthof the region compressed and sealed is sufficient to permit theconnected pouches to be separated from one another by cutting throughthe center of the seal without violating the integrity of the pouch oneither side, as indicated more clearly in FIGS. 3 a and 3 b. A secondembodiment of the tubing segment adapted to be subdivided into blood orplasma sample-containing aliquot portions is depicted in FIG. 2 a whichis a semi-schematic perspective view of a collection tubing segmentembodiment connected between a plasma donation bottle 20 and samplecontainer 28 and divided into aliquot-containing portions in accordancewith the present invention.

The collection tubing segment 50 is connected between the cap member 30of the test container 28 and the hollow elbow fitting 24 of the plasmadonation container cap. The tubing segment 50 suitably comprises aplurality of Y-sites 51 connected together in series by flexible,hollow, medical-grade plastic tubing segments 52. The Y-sites 51 are ofthe type commonly adapted for connection to an intravenous infusion setand include a cylindrical body portion 53 with a flow path definedtherethrough, having an outlet 54 at one end of the flow path and anaccess site 55 at the other end. A branch port 56 is provided along thebody 53 of the Y-site and includes a fluid path which is incommunication with the fluid path through the body 53.

One Y-site is connected to the next by solvent bonding a flexible,hollow, medical-grade plastic tube 52 between the outlet port 54 on thebottom of one Y-site to the branch port 56 of the next Y-site in theseries. An initial hollow entry tube 57 is solvent bonded to the branchport of the initial Y-site in the series. The initial entry tube 57 isconnected, in turn, to the elbow fitting 24 of the plasma donationcontainer cap. Connection may be made by friction-fitting the initialentry tube 57 onto the elbow fitting 24, sonically welding the tubethereto, or otherwise attaching the tube in a coaxial relationship withthe fitting by techniques well understood by those skilled in the art.Moreover, the initial entry tube 57 may terminate in a standardluer-type fitting 58 which would allow the series-connected Y-sites tobe removably connected to a donation container which was provided with amating luer-type connector at the end of the elbow 24.

In like manner, the terminal Y-site is fitted with a flexible, hollowterminal exit tube 59 which is solvent-bonded to the terminal Y-site atits outlet port. This tube may also be connected to a standard luer-typefitting at its distal end.

In a manner similar to that described in connection with the firstembodiment, after a plasma donation is taken from a donor and thedonation container 20 is filled, the donation container is tilted so asto raise the fluid level over the elbow fitting 24 connected to theentry tube segment 57. Plasma enters the tubing segment and flowsthrough the series-connected Y-sites, entering each Y-site through itsbranch port 56 and flowing into the next Y-site from the precedingY-site's outlet port 54. Plasma is decanted until the test container 28is filled. After the test container is filled, the donation is furtherdecanted until the series-connected Y-sites comprising the tubingsegment 50 are also filled.

After the plasma sample from the donation is drawn into the tubingsegment 50, the terminal exit tubing segment 59 is closed off by a heatseal or weld 40 a or other suitable sealing means such as a sonic weldat a suitable location along its length proximate to the terminal exittubing segments connection to the test container 28.

The filled tubing segment 50 is removed from the test container bycutting the terminal exit tubing segment 59 away from the test containerthrough the center of the seal 40 a. Alternatively, if the tubingsegment 50 terminates in a luer-type connector, the tubing segment 50 isremoved from the test container 28 by disconnecting the luer. A secondheat seal 38 a is applied to the initial entry tubing segment 57 at alocation along its length proximate to the initial segment's connectionto the donation container 20. The filled portion of the tubing segment50 is removed from the plasma donation by cutting the initial entrysegment 57 away through the center of the seal 38 a, or by disconnectingthe luer-type fitting 58, if such is provided. An elongated, hollow,articulated tube, closed off at both ends and comprising a plurality ofY-sites linked-together in series, is thus provided. Each of thelinked-together Y-sites contains an aliquot of the blood or plasmadonation.

As will be described in greater detail below, the tubing segmentsconnecting a preceding Y-site's outlet port to a subsequent Y-site'sbranch port are also provided with heat seals 42 a to define sequential,individual, and connected sample aliquots, each suitably comprising anindividual Y-site. Each such Y-site contains a particular quantity ofblood or plasma needed for a specific generation pool to be formed.Sealing to isolate each Y-site may be performed either after the tubingsegment 50 has been removed from the plasma donation container or may beperformed while the tubing segment is still attached. Preferably,sealing to isolate the Y-sites is performed while the tubing segment 50still attached to the plasma donation container so that the volumereduction caused flattening a portion of the tubing during the sealingprocess does not cause a build-up in the internal hydrostatic pressureof the sample. When the tubing segment 50 remains connected to theplasma donation container, excess fluid created by the volume reductionof the tubing created by the heat seals is allowed to be expressed backinto the donation container. Excess hydrostatic pressure, which may leadto dangerous spurting during sample extraction, is thus safely relieved.

Sealing may be performed by any known method, such as thermo-compressionsealing (heat sealing), sonic welding or the like, so long as the lengthof the region which is compressed and sealed is sufficient to permit theconnected Y-sites to be separated from one another by cutting throughthe center of the seal without violating the integrity of the tubingsegment on either side of the seal.

Turning now to FIGS. 3 a and 3 b, in a preferred embodiment, the sealbetween pouches (42 of FIG. 2) and/or Y-sites (51 of FIG. 2 a) includesa flat pad area 46, including a central narrow portion 47 through whichthe seal is cut or torn in order to separate the connected pouches.Cutting is done through the central portion in order to insure that eachseparated pouch remains sealed at compressed tab portions 48 at eitherend after separation. The length of the seal pad may be made greater orsmaller, depending on the chosen separation method. Separation may bedone by use of a scalpel, a guillotine cutter, or a simple pair ofscissors.

Turning to FIG. 4, an exemplary embodiment of a sealing device 60,useful for providing pouches of specific desired sizes, including meansto easily separate the pouches and identify their sequence number alonga segment, is shown. The sealing device 60 suitably comprises opposedfirst and second platens 61 and 62, respectively, each including aplurality of raised, seal head portions 63, arranged in a spaced apartrelationship on the opposing surfaces of the platen. The sealing device60 is preferably constructed such that the raised seal head portions 63are movable along their respective platens such that the spacing fromone raised seal head portion to another may be varied. The raised sealheads 63 may be arranged along the platen such that the distance betweensuccessive seal heads is made progressively smaller so that sealing isperformed along the length of a tubing segment at progressively closerspaced intervals. Thus, sample pouches of progressively smaller sizeand, therefore, progressively smaller volume content may be formed bymoving pairs of opposed seal heads along their respective platens to adesired location.

In order to form multiple heat seals along the length of the plastictubing segment filled with a blood or plasma sample, the tubing segmentis placed within the sealing device 60 between the upper and lowersealing platens 61 and 62, respectively. The opposed platens are broughtinto proximity with one another, thus compressing and sealing the tubingsegments. As depicted in FIG. 4, the plurality of spaced-apart, extendedor raised seal head portions 63 along the length of each platenalternate with recessed portions 64. As the opposed platens are movedtogether to form heat seals on those portions of a plastic tubingsegment filled with a blood or plasma sample compressed between theraised seal head portions 63, chambers are formed by the opposedrecessed portions 64. The chambers are provided in order to accommodatethose portions of the tubing segment which are not to be compressed but,rather, to be formed into pouches. Each chamber defined by each closedpair of recessed portions is configured to house a pouch.

A heater 65 is configured to heat each of the seal head portions of theplaten in order for opposed raised portions to form a heat seal on thetubing segment when the sealing device is closed. The heater 65 may beany one of well known heater types such as radiant heaters, induction orresistance heaters, or the like. The heater 65 is preferably connecteddirectly to each of the raised seal heads 63 to heat the raised portionswithout unduly heating the recesses. If desired, insulation can beprovided to reduce heat transfer between the raised portions and therecesses. In an exemplary embodiment, a cooling device 66, such ascooling or radiator fins, a moving air flow, or a cold finger, may alsobe connected to the sealing device 60. The cooling device 66 isconnected directly to each of the recessed portions 64 so that thechambers defined when opposed recessed portions move together aremaintained at a low temperature. Blood or plasma samples contained inpouches formed within the chamber during the seal process are thus notdamaged by the high temperatures of the heat seal.

The narrow area (47 of FIG. 3 b) through approximately the center of theseal is formed by an elongated ridge structure 67 provided down thecenter of the extended seal head portion 64 of the seal platens. As thetubing segment is squeezed between the upper and lower sealing heads,the ridge 67 forces an indentation on the top and bottom surface of theseal portion. The indentations narrow the plastic material comprisingthe center the seal, thus making it easy to separate.

In one embodiment of the invention, the ridge 67 may be serrated inorder to provide perforations disposed in a direction orthogonal to themajor axis of the tubing segments. The perforations allow the individualand connected pouches to be removed from one another without the dangerinherent with cutting with a sharp object of violating the integrity ofa pouch by inadvertently cutting through to the sample containing area.The perforations are preferably provided during the seal process byproviding the seal heads with serrations. Alternatively, perforationsmay be provided shortly thereafter by use of a separate perforating jigor die.

Means 68 are also provided to open and close the sealing device 60 inorder to compress the seal platens together and thus form seals alongthe length of the tubing segment. Such means are well known in the artand may suitably comprise a manual apparatus which opens and closes,such as a lever handle attached to one support frame and which moves theframe against, for example, a hinge. Other suitable arrangements mayinclude vertical guides, springs, or hydraulically operated pistonpresses, or other common mechanical, electrical, or hydraulic presses.

Turning now to FIG. 4 a, there is depicted in semi-schematic view, aspecific embodiment of a sealing device 70, useful for providingthermo-compression heat seals at uniform, spaced-apart intervals, so asto form pouches of specific desired sizes, or to isolate linked-togetherY-sites into individual sample-containing aliquots. The sealing device70 suitably comprises top and bottom platens 71 and 72, respectively,adapted to be mounted along the pressure lever and seal band,respectively, of a commercially available impulse sealer, such as one ofthe ALINE M-series impulse sealers, manufactured and sold by the ALINECompany of Santa Fe Springs, Calif. The specific embodiment depicted inFIG. 4 a is a two-part heat sealing head adapted to be attached to anALINE MC-15 Impulse heat sealer as an after market modification, andallows the MC-15 to produce pre-filled pouches of plasma for furtherprocessing in accordance with the system and method of the presentinvention.

The bottom platen 72 of the heat sealing head 70 is constructed of asuitable rigid, heat resistant material such as laminated Kevlar®manufactured and sold by the DuPont Corporation. In the illustratedembodiment, the bottom platen 72 is preferably about 15 inches in lengthin order to fit on the mounting surface of the MC-15 Impulse heatsealer. The bottom platen 72 includes a longitudinal slot 73 which iscentrally disposed and runs along the entire length of the bottom platen72. The width of the longitudinal slot 73 is approximately 0.2 inches inorder to accommodate standard medical tubing, which typically has anouter diameter of approximately 0.1875 ( 3/16) inches, in nested fashionalong the length of the slot.

A plurality of transverse slots 74 are provided at spaced-apartintervals along the length of the bottom platen 72 which are disposed ina direction orthogonal to that of the central slot 73. The transverseslots 74 have a width of approximately 0.5 inches and are located on1.125 (1⅛) inch centers. Each transverse slot is, therefore, separatedfrom its neighbors by a residual block of platen material centrallydivided by the central longitudinal slot 73 which is about 0.625 (⅝)inches in width.

Both the longitudinal and transverse slots 73 and 74, respectively, arecut only partially through the material of the bottom platen 72, therebyforming a substantially flat bed 75 which defines the bottom surface ofboth the longitudinal and transverse slots. When the apparatus is usedto form heat seals, a length of 0.1875 ( 3/16) standard medical tubingis nested in position along the longitudinal slot 73 and rests on thebed 75 of the bottom platen which functions as a bearing surface duringthe heat seal process.

A heating element 76, such as a nickel-chromium (NiCr) resistive wire,is provided in a snake-fashion from slot to slot and is disposedlengthwise along each transverse slot comprising the bottom platen inabout the center of the slot. Where the heating element 76 traverses thecenter of the transverse slots 74, the NiCr wire is protected fromcontacting the thermo-sensitive plastic tubing by covering the wire witha piece of, for example, Teflon® tape. Blood or plasma samples containedin the pouches formed within the sealing device during the seal processare thus not damaged by the high temperatures of the heat seal.

The top platen 71 is also approximately 15 inches in length and issuspended over the bottom platen 72 by the pressure lever of the MC-15heat sealer. The top platen 71 is constructed from a heat-resistantplastic material such as Lexan® or milled Kevlar® and comprises a set ofequally spaced-apart, generally rectangular teeth protruding from itsbottom, surface, and extending in a direction toward the bottom platen.The teeth 77 are about 0.5 inches in length and are spaced-apart on1.125 (1⅛) inch centers. Accordingly, it can be seen that each of theteeth 77 is dimensioned to fit into the cavity defined by the transverseslots 74 of the bottom platen 72. Each of the teeth 72 of the top platen71 is positioned to be suspended over a corresponding intersection of atransverse slot 74 and the longitudinal slot 73 of the bottom platen 72.Thus, each tooth 77 is configured to fit into the cavity thus definedwhen the heat seal platens are closed together by removal operation ofthe MC-15 device.

After a flexible tubing segment is placed within the longitudinal slot73, the top platen 71 is pushed into contact with the bottom platen 72,by lowering the lid of the MC-15 heat seal apparatus. As the lid islowered, the teeth 77 of the top platen 71 enter the cavity defined bythe transverse slots 74 of the bottom platen 72 and contact that portionof the tubing segment which lies exposed on the bed 75 at theintersection of each transverse slot 74 with the central longitudinalslot 73. Current is provided to the nickel-chromium resistive heatingwire which causes the plastic material of the tubing segment to soften.At the san time, the top platen 71 is compressed onto the bottom platen,thus applying pressure to the plastic material being softened by theheating element 76.

After sealing, the tubing segment is labeled on at least one end with aunique identifier that corresponds to the original plasma donation. Thismay be achieved by, for example, gluing a label onto the segment or byimprinting a bar coded emblem directly onto the tubing material. Aprepared recess 78 is suitably provided on the heat sealer 70 forholding and aligning a pre-printed bar code identifier tag. Such a tagis formed from a suitable heat-sealable material and is heat sealed tothe tubing segment at the first seal position for identificationpurposes. The tubing segment, including the sample containing pouches,is then frozen for preservation.

Returning to FIG. 2, it is important to be able to unambiguouslyidentify all of the various parts of the system that comprise anindividual plasma donation. Thus, unique identifiers such as codedthreads, coded dots, bar codes, or other structure coded with the uniqueidentifier, may be placed in the physical structure of the plasmacollection system. For example, in one embodiment, a coded thread 37 ismolded into the donation container 20, a coded thread 39 is molded alongthe edge of the bottle cap 22, a coded thread 41 is molded along theside of the test container 28, and a coded thread 43 is molded into thetubing segments at spaced-apart intervals. The unique identifier in thetubing segment runs along the length of the tubing segments and the codeis repeated in order to permit segmentation of the tubing segments whilemaintaining identification integrity of each segment so prepared.Furthermore, each portion of the donation system is identified with thesame code so that donation identity is maintained for all parts of thesystem.

Returning now to FIGS. 3 a, 3 b, and 4, it may be further desirable tohave each individual pouch along a segment identified by an alpha ornumeric code equal to the position of the pouch along the linear lengthof the original tubing segment. Such code may be imprinted, for example,on the compressed portion of the seal pad located between adjacentpouches by use of a stamping die. Such a stamping die may comprise anintegral part of the sealing device as depicted in FIGS. 4 and 4 a, sothat sealing, forming pouches of variable sizes, and providing narrow orperforated areas for easy separation, as well as identification numbers,are all accomplished in a single efficient step. Alternatively, thealpha or numeric identifier could comprise part of a perforating jig ordie. Stamping dies are known which include means for advancing the alphaor numeric character to a next sequential one such that sequentialpouches in a tubing segment are each identified by a correspondingsequential string of alpha (a, b, c . . . ) or numeric (1, 2,3, . . . )characters.

Therefore, if a first testing pool is being prepared from pouches fromseveral donations, a quality control check may be performed byconfirming that all pouches to be pooled from each tubing segment havethe same location code, for example, number 1. Likewise, when preparinga second testing pool from samples of the same donations, a qualitycontrol check may be performed by confirming that all pouches to bepooled from each tubing segment have, for example, the number 2imprinted at some point on the compressed portion of the pouch.

In order to effect efficient PCR testing of a donation, the serologytest sample taken from each individual donation in test container 28 istested for various known antigens and/or antibodies which are designatedfor specific viruses. If a sample is positive for one or more knownantigen or antibody tests, the individual donation and its correspondingtubing segment are excluded from further testing and both may bedisposed of in an appropriate manner.

Tubing segments corresponding to the remaining serology negativedonations are divided into identified groups, each group comprising aselected number of donations. As will be described further below, thenumber of donations per group is determined by the sensitivity of thespecific high-sensitivity tests, such as a PCR test, the anticipatedconcentration of the viral RNA or DNA of interest in the plasma sample,and the anticipated frequency of a PCR positive sample occurring withinthe general donor population. For example, for the detection of thehepatitis C virus, containing the RNA of interest, in a population ofrepeat plasmapheresis donors, it is appropriate to pool samples ofbetween 100 and 700 individual donations. For a population in whichviral contamination occurs more often, smaller pools of between 50 and100 individual donations may be appropriate.

One embodiment of a process of preparing a PCR testing pool inaccordance with the present invention will now be described inconnection with FIGS. 5 and 6. A sampling plate 80, generally similar inapplication to a titer plate but configured in accordance with practiceof the invention, is provided. The sampling plate 80 is configured tocontain generally hemi-cylindrical sample wells 81 disposed horizontallyon the plate in a generally regular array. A suitable sampling plateused to practice the method of the invention has 64 such sample wellsarranged in a 8×8, row/column, rectangular fashion. A cover plate 82having approximately the same exterior dimensions as the sampling plate80 is also provided. The cover plate 82 is adapted to cover the surfaceof the sampling plate 80 in close-fit attachment. Through-holes 83 arearranged on the cover plate in the same array fashion as the samplewells of the sampling plate 80. When the cover 82 is placed over thesurface of the sampling plate 80, through-holes 83 line up verticallyover the sample wells 81, thereby allowing communication with the samplewells through the through-holes. The diameter of the through-holes issubstantially smaller than the surface area of the test sample pouchesand the corresponding sample wells. However, the through-hole diameteris sufficiently large to permit a needle or other cannula like object topass through the holes and enter the sample wells beneath.

As shown in connection with FIG. 6, a terminal (first generation,“number 1”) pouch 84 is removed from each tubing segment that has beenidentified as belonging to a particular PCR group to be tested. Eachterminal pouch 84 is washed, but not opened, and placed in acorresponding sample well 81 of the sampling plate 80. The cover plate82 is secured over the top of the sampling plate 80 and the plate,cover, and pouches are thawed at an appropriate temperature.

An equal volume of between about 0.02 to 0.5 ml of plasma is removedfrom each pouch and pooled in a testing container. A needle 85 or othercannula like device is inserted through the through-hole in the coverplate and into the sampling plate sample well directly below, therebypiercing the tubing material of the side wall of the pouch and gainingaccess to the plasma sample therein. In an exemplary embodiment, theneedle is connected to a device that provides a continuous vacuum orsuction to extract all of the blood or plasma contained in the pouch andminimize any leakage of fluid into the surrounding tray. The needle maybe held in a device which allows the needle to move through thethrough-hole and top wall of the pouch, but restricts its downwardprogress so that the needle is prevented from touching or piercing thebottom wall of the pouch as the pouch sits in the sample well. When thecannula is withdrawn after extracting a sample, the cover plate material86 surrounding the through-hole prevents accidental withdrawal of thepouch along with the cannula, as depicted in FIG. 6.

While the method of preparing a PCR test pool has been described interms of manually extracting a sample by inserting a cannulaindividually into each sample well, the method may equally be practicedusing an automated process. The sampling plate containing pouches ineach well may be held so as to allow an array of cannulas, arranged in amanner corresponding to the arrangement of through-holes in the coverplate, to be pressed down onto the sampling plate, thereby allowing allof die sample pouches to be pierced and samples extracted therefrom atthe same time. Alternatively, a single cannula or cannula holding devicemay be automated or programmed to successively pierce and withdraw fluidfrom each pouch. In order to prevent carryover contamination, a cleancannula is used to withdraw samples for each pool.

In addition, it will be evident to one having skill in the art that thecombination of sampling plate, sample wells, cover, through-holes, andcannula, while described in connection with extracting sample fluid froma sample packet, is equally applicable to extracting sample fluid fromthe Y-site sample containers of FIG. 2 a. The configuration of thesample wells of FIGS. 5 and 6 are determined by the shape of thefluid-holding container, and only minor modifications are required toreconfigure them for Y-sites. For example, the sample wells may comprisean elongated cylinder, oriented vertically, into which each Y-site isinserted. A notch may be provided at some appropriate location about theupper periphery of each sample well which functions as a detent intowhich the Y-site's branch port may be positioned. This would alsofunction to orient each Y-site and provide additional positionalsecurity. In the same manner as described in connection with FIGS. 5 and6, fluid may be extracted from each Y-site by inserting a cannulathrough each Y-site's access port and into fluid communication with thesample. As the cannula is removed from the access port, the cover platematerial surrounding each through-hole acts as a stop and prevents theY-site from being withdrawn from the sample well.

It will be further evident to one having skill in the art that thisconfiguration is equally suitable for practice of the invention using anautomated process. An array of cannulas may be arranged in a mannercorresponding to the arrangement of through-holes in the cover plate,thereby allowing all of the access ports of the Y-sites to be piercedand samples extracted therefrom at the same time. Alternatively, asingle cannula or cannula holding device may be automated or programmedto successively pierce each access port and withdraw fluid from eachY-site.

An additional embodiment of an apparatus and method suitable forpreparing a PCR testing pool in accordance with the present inventionwill now be described in connection with FIGS. 7, 8, 9 a, 9 b, and 10.Turning first to FIG. 7, a plasma donation pool comprising expressedfluids from a multiplicity of plasma samples is prepared from a numberof plasma donation sample packets in an electrically powered hydraulicpress 90. The hydraulic press 90 suitably comprises a crushing cylinder91 in which sample packets are placed, and a hydraulically operatedpiston 92 which crushes the sample packets. The samples contained withinthe packets are expressed from the crushing cylinder 91 by a suitablecompressed gas, such as compressed air or nitrogen, and collected in apooling container as a pool.

Initially, a generational pouch (for example, pouch #1) is removed fromeach tubing segment that has been identified as belonging to aparticular PCR group to be tested. Each generational pouch is washed,but not opened, and placed within the crushing cylinder 91 of the press90. Loading of the crushing cylinder is performed within the environmentof a class II biosafety hood and air-flow path so as to ensure againstinadvertent contamination of the surrounding environment by a packetwhich has lost structural integrity. In a manner to be described ingreater detail below, the crushing piston 92 is firmly seated into theopen throat 91 a of the crushing cylinder 91 in such a manner thatcontainment of the contents of the crushing cylinder 91 is assured andthat the cylinder 91 and piston 92 combination completely encloses thesample packets. The manner in which the crushing piston 92 engages thecrushing cylinder 91 is designed to ensure that the environment outsideof the cylinder 91 is protected from contamination by any harmfulviruses that may be present in any of the samples contained by thesample packets.

The crushing cylinder 91 is next mounted on a cylinder seat 93 whichaligns the cylinder in correct position on the hydraulic press 90 andfurther allows a hydraulic shaft 94, operatively connected to ahydraulic cylinder 95, to align with and mate to the crushing piston 92.In a manner that will be described in greater detail below, the crushingpiston 92 is releasably connected to the hydraulic shaft 94, such thatthe piston 92 can be both raised and lowered by operation of thehydraulic cylinder 95.

After the cylinder 91 and piston 92 have been properly aligned on thecylinder seat 93 and connected to the hydraulic cylinder 95 through theshaft 94, a control valve 96 is operated so as to cause the hydrauliccylinder to exert a force on the shaft 94 and piston 92 which, in turn,crushes the sample packets within the crushing cylinder 91. Thehydraulic cylinder 95 operates in conjunction with a four horsepower 240volt AC electric motor 97 which operates a hydraulic reciprocating pump98 which pumps hydraulic fluid in conjunction with a fluid reservoir 99to thereby operate the cylinder 95. About 4,000 lbs of force is pointloaded at the hydraulic shaft 94 which develops a pressure of about 800to 900 psi applied to the sample packets by the piston 92.

After the sample packets have been crushed, the fluid donation samplescontained therein are expressed from the crushing cylinder 91 by acompressed gas supplied by, for example, a compressed air cylinder 100which is connected through a pressure regulator 101 to a pop-off valve102 provided in the crushing piston 92. In order to allow the pop-offvalve 102 to operate correctly, the piston 92 is first raised slightlyfrom its fully extended crushing position. Compressed air is vented intothe cylinder 91 through the pressure regulator 101 until the thresholdpressure of the pop-off valve is reached. The valve 102 then opens,allowing the compressed gas to pressurize the interior of the cylinderwhich forces the plasma pool out of the crushing cylinder 91 through acollection port 103 provided in the bottom of the cylinder. The plasmapool is then collected in a pooling container connected to thecollection port 103 by an express line or tube as the fluid is forcedout of the cylinder by the compressed air. The compressed air isexhausted into a class II biological safety hood, after passage througha bleach trap.

Turning now to FIG. 8, there is depicted a cross-sectional, partiallycut-away view of a crushing cylinder 91 constructed in accordance withprinciples of the invention. The crushing cylinder 91 suitably comprisesa generally circular base plate 105 having a top and bottom surface anda circumferential lip 106 extending in an upwardly direction from thetop surface, with threads cut into its interior face. A cylindricalcylinder wall 107, open at both ends, is threaded on the exterior faceof its bottom end. A rabbet or notch 108 is cut into the interior faceof the bottom end of the cylinder wall 107 so as to define an annularlip 109 which is disposed parallel to the top surface of the base plate105 and presents an opposing face thereto. As the cylinder wall 107 isscrewed into the base plate 105, a screen plate 110 disposed on thesurface of the base plate 105 is engaged by the annular lip 109 of thecylinder wall 107 and compressed between the annular lip 109 and the topsurface of the base plate.

Turning now to FIGS. 9 a and 9 b, the screen plate 110 is a generallycircular, disc-shaped plate against which the sample containing packetsare forced when they are crushed by the crushing piston 92. As isdepicted in FIG. 9 b, the screen plate 110 includes fluid gutterscomprising radial slots 111 and concentric circular slots 112, allapproximately 1/32 inches in width, which are cut in the top surface ofthe screen plate. The radial slots 111 are cut at an angle which slopestoward the center of the screen plate 110 where they terminate into anaxially located drain or sump 113 which drains through a ¼ inch drainpipe 114 (best seen in FIG. 8) drilled through the base plate 105.

Returning now to FIG. 8, a seal is formed between the cylinder wall 107and the screen plate 110 by engaging and compressing an O-ring 115,provided in a seal race 116 cut into the base plate 105 for suchpurpose. The seal race 116 is located in the base plate such that theO-ring 115 lies beneath the vertical intersection of the screen plate110 and the cylinder wall 107. A step 117 is cut into the base plate105, and a mating groove 118 is cut into the screen plate, so that apositive detent is able to precisely locate the screen plate onto thebase plate for proper alignment with the O-ring such that the cylinderwall 107 will properly engage the screen plate and their intersectionwill properly engage the O-ring 115.

Turning now to FIG. 10, there is depicted, in cross-sectional partialcut-away view a crushing piston 92 provided in accordance withprinciples of the invention. The crushing piston 92 comprises agenerally cylindrical piston head 120, having an axially extending,centrally located cup 121 protruding therefrom, the cup 121 havinggenerally cylindrical walls and one open end to define thereby a socket123 for receiving a generally cylindrical hydraulic cylinder shaft 94.

An annular flange 122 is provided around the circumference of thecylindrical cup 121, and surrounds the cup's open mouth. The outersurface of the flange 122 is beveled, such that the beveled surfaceincreases in diameter in the direction towards the bulk body of thepiston head 120. As the hydraulic shaft 94 is advanced into the socket123, a pair of spring-loaded retaining clips 124 are advanced over thebeveled surface of the annular flange 122 until they detent intoposition and grip the underside of the annular flange.

To accommodate mating with the socket 123, each retaining clip 124includes a beveled tooth 125 which rides along the beveled surface ofthe piston head's annular retaining ring 122, thereby spreading open thejaws of the spring loaded retaining clips 124. As the hydraulic shaft 94continues to advance, the beveled teeth 125 of the retaining clips 124are eventually advanced past the beveled surface of the annularretaining ring 122. The spring loading of the retaining clips forces thebeveled teeth into contact with the outer surface of the cup side wall.The teeth of the retaining clips 124 are thus engaged with the undersidesurface of the annular retaining collar 122, thereby gripping thecrushing piston 92 and providing means for causing the piston to move inboth directions.

In addition, it will be evident to one having skill in the art that thespring loaded retaining clips 124 may be easily disengaged from theannular retaining ring 122 by a simple squeezing together of the ends ofthe clips opposite the beveled retaining teeth 125. Accordingly, it willbe seen that the piston head 120, the cylindrical, axially mounted cup121, the annular retaining ring 122 and the retaining clips 124, incombination, provide means for quickly and easily disconnecting thehydraulic shaft 94 from the crushing piston 92. This quick-disconnectfeature allows the piston 92 and cylinder 91 combination to be easilyremoved from the cylinder seat 93 of the hydraulic pressure 110 forcleaning, sterilization, refilling with additional sample packets, andthe like.

As is shown in FIG. 10, the crushing piston 92 further includes severalO-rings 126 disposed in seal races 178 provided about the periphery ofthe piston head 120. The O-rings are provided in order to form a tightpressure seal between the exterior circumferential surface of the pistonhead 120 and the inner circumferential surface of the cylinder wall 107of the crushing cylinder 91. Multiple O-ring seals provide a measure ofsafety and security, in order to ensure containment of potentiallycontaminated sample fluid within the confines of the cylinder 91. Whilethree O-rings 126 are depicted in the illustrated embodiment of FIG. 10,it will be evident that a greater or lesser number of O-ring seals maybe provided in accordance with the invention. All that is required isthat a seal be formed between the crushing piston 92 and the crushingcylinder 91 so as to ensure containment of potentially contaminatedfluid within the cylinder.

Returning now to FIG. 8, the crushing cylinder side wall includes a0.020 inch beveled step 130 which is machined into the interior surfaceof the side wall. The first approximately 1.0 inches from the top, ofthe cylinder side wall 107 is thus, machined to have an inside diameter(ID) approximately 0.040 inches larger than the ID of the remainingportion of the cylinder side wall 107 which extends downwardly towardsthe screen plate 110 and base 105. The interface between the step andthe remaining side wall portion is beveled, so as to provide arelatively smooth, angled transition from the slightly larger upper ID,to the slightly smaller lower ID.

The step on the cylinder side wall 107 is provided so that the crushingpiston 92 may be manually inserted into the open throat of the crushingcylinder 91 with wily slight contact being made between the O-rings (126of FIG. 10) and the ID surface of the cylinder. Once the manuallyassembled piston and cylinder combination is placed on the cylinder seat(93 of FIG. 7) the hydraulic shaft 94 is advanced to mate with thesocket 123 of the piston and is extended until the retaining clips 124detent against the underside surface of the piston head's annularretaining collar 122. The hydraulic shaft 94 is then further advanced soas to push the piston further into the cylinder, thereby pushing theO-rings beyond the step 130 on the ID of the cylinder wall. When pushedbeyond the step, the O-rings fully compress between the ID of thecylinder side wall 107 and the piston seal races 127, forming thereby atight seal.

In operation, the crushing piston 92 develops pressure of about 800 to900 psi (4,000 lbs of force point loaded at the hydraulic shaft) whichis a sufficient pressure to crush the sample packets contained withinthe cylinder. Blood or plasma sample fluid flows along the fluid gutterprovided in the screen plate and into the central sump, where it iscollected and allowed to flow out the extraction port and into a poolingcontainer. Following the crushing operation, the hydraulic cylinder 95is operated to raise the crushing piston 92 a small distance(approximately ½ to 1 inches) above the mass of crushed sample packets,thereby creating a chamber within the cylinder. A pressurized gas, suchas compressed air, is forced into the chamber through the pop-off valve102 in the piston 92. Pressurizing the chamber causes any remainingblood or plasma sample fluid to be expressed out of the cylinder throughthe outlet port 103 into the pooling container.

Once the crushing and pooling operation is completed, the express lineconnected to the outlet port 103, is clamped, to prevent any additionalsample fluid from exiting the cylinder. The express line is placed intoa bleach container, and the hydraulic cylinder 95 is caused to raise thepiston further in the cylinder, thereby creating a suction which siphonsbleach from the container into the cylinder. Preferably, the crushingand bleach siphoning steps are repeated two additional times, in orderto ensure that any blood or plasma sample “flash back” fluid is fullyexpressed from the crushing cylinder 91 and that the bleach has ampleopportunity to fill the interior volume of the crushing chamber, therebyreducing any gross viral contamination that may be found within.

Next, the quick release clamps are operated and the piston/cylindercombination is removed from the hydraulic press 90 and subjected tosterilization procedures in, for example, an autoclave. The piston andcylinder may be subsequently chemically cleaned by soaking them in a 10%bleach solution for fifteen minutes, followed by a rinse cycle of H₂0,1% SDS (sodium dodecyl sulfate) surfactant, and H₂0 again, prior toautoclaving. If there is insufficient time for autoclave sterilization,the chemical clean may be concluded with a 70% ETOH and sterile H₂0solution. If such additional chemical cleaning is desired, it isperformed in a class II biosafety hood which exhausts through a HEPAfilter. While under the hood, the crushing cylinder is loaded with anext group of sample packets to be crushed and the crushing piston 92 ismanually inserted into the open mouth of the crushing cylinder 91 andforced down until the pistons O-rings make contact with the beveled stepformed in the side wall of the cylinder. The newly reloadedcylinder/piston combination is now ready to be placed on the cylinderseat 93 of the crusher 90. The hydraulic cylinder 95 is operated tocause the hydraulic shaft 94 to lower onto the piston 92 such that thequick release clamps engage the annular retaining ring on the piston.The crushing, expressing, and bleach-cleaning process is now repeated.

From the foregoing, it will be evident to one having skill in the artthat the electrically operated hydraulic press (the crusher) 90 allowsharvesting of blood or plasma samples from a great number of samplepackets in a minimal amount of time. The number of sample packets ableto be crushed by such an apparatus is limited primarily by the scale ofthe device and the pressure able to be developed by the crushing pistonagainst the mass of sample packets contained in the cylinder. The 800 to900 psi of pressure developed by the hydraulic press of the illustratedembodiment is sufficient to completely crush up to 64 sample containingpackets of the type described in connection with FIG. 2. Accordingly,large scale pools comprising up to 512 samples, can be formed by 8operation cycles of the crusher of the present invention. This wouldprovide a significant reduction in pool formation time over a method inwhich 512 sample packets were individually accessed by a cannula toharvest the samples therefrom.

In addition, it will be apparent to one having skill in the art that asingle large scale pool, comprising up to 512 samples or more, can beformed from a crusher apparatus made sufficiently large enough toaccommodate the greater number of sample pockets in the cylinder. Thehydraulic press portion would also be increased in size to providegreater crushing power to overcome the greater resistance of theincreased number of pockets. As was mentioned above, the pool size wouldonly be limited by the desired scale of the crusher.

Referring now to FIG. 11 there is shown a flow chart of a PCR testmethodology according to the invention, which allows for theidentification of a unique PCR positive donation with the fewest numberof individual tests.

The process begins at block 200 with the definition of an appropriateinitial pool size which, in turn, depends on various factors such as thefrequency of occurrence of the virus of interest in the general donorpopulation, the likely final concentration of viral DNA or RNA afterdilution in the pool, and the like.

Although the PCR test is highly sensitive and is capable of detecting asingle virus in a contaminated sample, a virus must necessarily bepresent in the sample for the PCR test to provide a positive result. If,for example, a sample from a contaminated donation having a relativelylow virus concentration is pooled together with a large number ofuncontaminated samples, the concentration of virus in the resulting poolmay be so low that there is a statistical probability that no virus ispresent in a sample taken from the pool for PCR testing. Such pools may,indeed, falsely test negative for viral contamination.

For example, if a 0.02 ml sample was prepared from a plasma donationcontaminated with viruses at a concentration of 500 viruses per mll ofsample, the 0.02 ml sample would comprise, on average, 10 viruses. Ifthis 0.02 ml contaminated sample were pooled with approximately 500other 0.02 ml samples from uncontaminated donations, the resulting 10 mlpool would comprises viruses at a concentration of 1 per ml.Accordingly, if a 1 ml sample were taken from the pool for PCR testing,there is a significant statistical probability that the PCR sample willcontain no viruses.

Such low concentrations of virus contamination pose little threat forproducts produced from plasma, because several methods are available forinactivating viruses present in such low concentration donations. Suchviral inactivation methods include the use of solvent/detergent orheating at over 60° C. for an appropriate time or the like. Thesemethods, generally, are described as being capable of reducing theconcentration of viruses by a number of “log units.” For example, thesolvent detergent method is capable of reducing the viral contaminationof hepatitis C by at least 10⁷ per ml or “7 log units.” Thus, plasmaproducts such as factor VIII, factor IX or prothrombin complex may beprepared from plasma donations routinely treated by, for example, thesolvent detergent method after having been PCR tested negative.

For blood products, routinely transfused directly to a recipient, thereremains some small risk of low concentration viral contamination, aftersuch donations have PCR tested negative.

In the embodiment illustrated in connection with FIG. 11, the factorsdiscussed above, such as the frequency of occurrence of the virus ofinterest in the donor population and the likely concentration of thevirus alter dilution, are evaluated. An appropriately sized first levelPCR testing pool is designed which minimizes the statistical probabilitythat viruses present in low concentrations will go undetected. The poolis prepared at block 201 by pooling the contents of terminal pouches ofidentified tubing sections, in the manner described above. At block 202,a PCR test is performed on the first level PCR pool.

Block 203 represents a decision point in the methodology of theinvention which depends on the results of the PCR test performed inblock 202. In the event of a negative result on the test, all of thedonations corresponding to samples used to make up the first level PCRpool are presumed to be free of viral contamination and released forfurther processing into pharmaceutical products. The methodology thusexits on receipt of a negative PCR test result. When the PCR testreturns a positive indication, this indicates that a viral contaminantis present in one, or more than one, of the donations which made up theoriginal PCR first level pool. At block 204, an additional sample pouch,the pouch next to the one first removed, is taken from tubing segmentswhich correspond to donations comprising the original PCR first levelpool. These additional sample pouches are divided into two approximatelyequal subgroups, designated A and B herein for purposes of clarity.

These subgroups are then separately pooled using a separate, cleancannula to form each subgroup pool in the same manner as describedabove, and only one of the subgroup pool is PCR tested, as indicated atblock 205. It is immaterial for purposes of the invention which of thetwo subgroups is tested. In block 205, subgroup A is identified as thesubgroup to be tested, but subgroup B could just as easily have beendesignated without disturbing the methodology of the invention.

At block 206, a decision is made depending on the outcome of the PCRtest of subgroup pool A. In the event that subgroup pool A testsnegative for a PCR viral indication, no further testing is performed onsamples from donations that comprised subgroup A. Rather, as indicatedat block 207, the next sample pouches in sequence are taken from tubingsegments that comprised subgroup B which are then, in turn, divided intotwo approximately equal subgroups A′ and B′. Each subgroup in this stepcomprises approximately half the number of samples as comprised theimmediately preceding subgroup. The contents of the subgroup samplepouches are again pooled separately in the same manner as describedabove. In the event that subgroup A tested PCR positive, indicating atleast one of its component donations was virus contaminated, the otheruntested subgroup (subgroup B in the example of FIG. 11) is now PCRtested at block 108 to confirm that it is not also PCR positive.Subgroup A now becomes the subgroup further subdivided into twoapproximately equal subgroups (A′ and B′), as indicated at block 209.

At block 210, PCR testing is performed on only one of the subgrouppools, A′ or B′, defined in preceding step 207 or 209. The method nowiterates and returns to block 206, wherein the decision step is appliedto the results of the PCR test performed at block 210. Again, if the PCRtest results prove negative for the tested subgroup, the untestedsubgroup would be further subdivided into two approximately equalsubgroups, each comprising approximately half the samples of thepreceding subgroup. If the tested subgroup returned a PCR positiveresult, the tested subgroup would be further subdivided into twoapproximately equal subgroups, each of which would comprise one half ofthe samples of the preceding subgroup. In this case, the untestedsubgroup would again be PCR tested in order to confirm that it was notalso PCR positive.

The test methodology continues iterating from block 206 through block210 until testing is determined to be complete. Test completion isdefined as when a subgroup division results in the creation of twosubgroups, each containing only one sample pouch corresponding to asingle donation. One of the samples is PCR tested at block 210 and, ifthe test results are negative, the other sample is identified asbelonging to a virally contaminated plasma donation. If the testedsample tests positive, the remaining sample is then also PCR tested inorder to confirm that it is not also PCR positive.

Upon completion of all testing, the methodology of the invention ends atblock 211. It should be clear from the flow chart of FIG. 11, that thetesting methodology of the invention only requires that two PCR tests beperformed at each test level when the initially tested pool is positive:One initial test for one of the two subgroups, and one subsequent testto confirm that the corresponding initially untested pool is indeednegative. The test methodology requires only a single PCR test at eachtest level when the initially tested pool is negative.

Application of the system and method for sample testing of the inventionwill now be described in connection with a particular PCR test poolsize, as depicted in FIG. 12. In FIG. 12, the terminal pouches of 512individual donations are formed into an initial PCR testing pool at 212.For purposes of illustration, it will be assumed that only one of the512 samples was taken from a donation which was contaminated by a virusof interest. The tubing segment depicted in FIG. 12 which comprises 10individual and connected pouches represents the tubing segmentsoriginally connected to and taken from the contaminated plasma donationcontainer.

The initial 512 sample pool is PCR tested and because of the presence ofthe contaminated sample, returns a positive viral indication. At step213, two 256 donation pools (256A and 256B) are prepared from the nextsequential pouches taken from segments that made up the prior positivepool. Pool 256B is now PCR tested and, as depicted in FIG. 12, returns anegative viral indication, thus indicating that pool 256A contains asample from the contaminated donation.

At step 214, two 128 donation pools are prepared from the nextsequential pouches of tubing segments that made up pool 256A. Thus,according to the invention, pool 256A has been subdivided without havingbeen PCR tested. At step 203, pool 128A is now PCR tested and, since itreturns a negative viral indication, pool 128B is now known to include asample pouch from the contaminated donation. Pool 128B is thensubdivided into two 64 donation pools (64A and 64B) by removing the nextsequential pouch from those tubing segments whose preceding pouches madeup pool 128B.

Next, pool 64B is PCR tested and, in the example of FIG. 12, returns apositive viral indication. In this case, PCR testing is performed onpool 64A in order to verify that it is, indeed, negative and that noadditional contaminated samples are present beyond those in pool 64B. Atstep 216, pool 64B is further subdivided into two 32 donation pools, 32Aand 32B, by removing the next sequential pouch from tubing segments usedto make up preceding pool 64B. Pool 32B is PCR tested, returns anegative viral indication, as indicated, and pool 32A is thereforefurther subdivided into two 16 donation pools, 16A and 16B. Again, the16 donation pools are prepared by removing the next sequential samplepouch from tubing segments that made up the preceding positive pool,32A.

At step 217, pool 16B is PCR tested and returns a positive viralindication. Pool 16A, therefore, is PCR tested in order to confirm thatit is negative, and that all contaminated samples are present in pool16B.

At 218, pool 16B is subdivided into two 8 donation pools, 8A and 8B, byremoving the next sequential sample pouch from tubing segments that madeup the preceding positive pool 16B. Pool 8B is then PCR tested and, asillustrated, returns a negative viral indication, indicating that pool8A contains a sample from a contaminated donation. Pool 8A is thenfurther subdivided into two 4 donation pools, 4A and 4B, at step 219.PCR testing is performed on pool 4B, which returns a negativeindication, thus indicating that pool 4A contains a sample from acontaminated donation. Pool 4A is then subdivided, at 220, into pools 2Aand 2B in the same manner, as described above. Upon PCR testing, pool 2Areturns a negative viral indication indicating that one of the twosamples comprising group 2B was taken from a tubing segment of acorresponding contaminated donation.

At step 221, the individual donations are tested by removing the finalpouch from the tubing segments that made up group 2B. The finalindividual donations are PCR tested in order to identify the specificpositive donation, which is then removed from storage and appropriatelydisposed of. The remaining 511 viral free donations are retained forfurther processing into pharmaceutical products.

In the above example, a single contaminated donation has been uniquelyidentified from a group of 512 such donations, by performing only 13separate PCR tests, including the primary PCR test on the original 512donation pool. The method of the invention, allows for skipping a PCRtest on a particular subpool, so long as the corresponding testedsubpool returns a negative viral indication. By thus skipping certainPCR tests, the method of the invention reduces the number of PCR teststhat must be performed in order to identify a specific positivedonation, without sacrificing the resolution of the PCR testmethodology. Under the method of the invention, all positive donationswill be identified but without requiring that all donations be tested.

From the exemplary embodiment of FIG. 12, it will be clear that eitherone of the successively smaller subgroups may be PCR tested and that thearbitrary position of the positive sample may be varied. Thus, if asample from the positive donation were present in each initially testedsubpool, 18 tests would be required to uniquely identify the positivedonation (one initial test which returns a positive indication and oneadditional test to assure that the corresponding subpool is negative).

By the same token, if each initially tested subpool returns a negativeindication, 10 tests would be required to identify the positivedonation. In practice, positive and negative test results on thesubpools would tend to distribute equally, thus, 14 tests on averagewould be required to identify a uniquely positive donation from aninitial donation pool for 512 units.

It is therefore clear from the foregoing that the system and method ofthe present invention, including the provision of tubing segmentscomprising individual and connected pouches each containing a sample ofa plasma donation, is advantageous in providing a multiplicity of PCRtest pools. Unlike conventional pool preparation, in which a sequence ofinitial and subsequent pools are formed from a single sample of eachdonation at the same time, the present invention allows for formation ofa test pool immediately prior to testing. This manner of “just-in-time”pool formation permits construction of test pools from individualpouches only as needed. The possibility of contamination is eliminatedsince the pools are constructed at different times, each from sealedsample pouches. Moreover, sample pouches remain frozen until needed todevelop a test pool. Multiple freeze-thaw cycles which may adverselyaffect the recovery of the DNA or RNA of interest are avoided, thusinsuring the integrity of the PCR test.

While the above-described method is effective for identifying a viralpositive donation with the fewest number of relatively expensive PCRtests, other methods for identifying individual positive donations arealso provided in accordance with practice of the present invention. Inparticular, one such method has the property of being able to identifyindividual positive donations within two to three PCR testing cycles,thus significantly reducing the amount of time and administrativeoverhead required to screen a large number of donations.

For example, in the above-described method, once a particular subpoolhas been identified as containing a positive donation, a technician mustidentify those donations which contributed samples to form thatparticular subpool. Those donations must then be revisited, and anadditional sample packet must be harvested from each correspondingtubing segment. Two next-generation subpools must then be formed, andPCR testing repeated. This harvesting, subgroup pool formation, and PCRtesting process is repeated for smaller and smaller generationalsubpools until the method uniquely identifies the virally contaminateddonation.

However, a significant amount of time is consumed in each PCR testingcycle (harvesting, subgroup pool formation, and PCR testing). Talkingthe 512 sample first generational pool as an exemplar, it will beevident that at least 10 PCR testing cycles will be required to identifya unique viral contaminated donation. While highly cost-effective, theabove-described method may present challenges to a PCR testinglaboratory when time is of the essence.

A methodology for uniquely identifying viral positive blood or plasmadonations in the fewest number of PCR testing cycles will now bedescribed in connection with FIGS. 13 and 14.

Turning now to FIG. 13, there is depicted a flow chart of a PCR testingmethodology, in accordance with the invention, for efficiently detectinga PCR positive individual donation in a pool with the minimum number ofPCR analysis cycles. As was the case with the prior-described PCRtesting method, the method of FIG. 13 assumes that the PCR test hassufficient sensitivity to detect the presence of a positive sample in apool of the appropriate size. For purposes of illustration only, theinitial grouping has been chosen to represent 512 blood or plasmadonations. It will be understood by those having ordinary skill in theart that the initial grouping size may be larger or smaller depending onthe particular genome marker being evaluated, the sensitivity of the PCRtest procedure used, the expectation value of the genome markerconcentration within a sample aliquot, and the sample aliquot size.

The method begins in block 301 by defining an N-dimensional samplematrix or grid. The matrix may be of any size and comprise any number ofdimensions from 2 to N, but preferably is a 3-dimensional regularmatrix, organized as a square.

An example of such a matrix is depicted in FIG. 14, which is a graphicalillustration of square matrix, characterized by 3-dimensional; row,column, and slice (r,c,s). In the exemplary matrix of FIG. 14, there are3 rows, 3 columns, and 3 slices, thereby defining 3³, or 27, elements.In the exemplary embodiment, a row is considered as comprising all ofthe elements defined by taking an imaginary vertical section through thesquare regular matrix. In the embodiment of FIG. 14, the elementscomprising, for example, row 3 of the matrix are identified by theletter r₃ on their row faces.

Likewise, a column comprises all of the matrix elements defined bytaking a second imaginary vertical section through the matrix, in adirection orthogonal to the direction of a row. In the exemplaryembodiment of FIG. 14, the elements that comprise, for example, column 1have the letter c₁ on their column faces. A slice is defined as allelements comprising a horizontal section taken through the exemplarymatrix of FIG. 14. In like manner to the row, column, definition, theelements comprising slice 1 are identified with the letter s₁ on theirslice faces.

It can be seen, therefore, that each of the 27 elements in the matrix ofFIG. 14 uniquely belongs to 1 of the 3 rows, 1 of the 3 columns, and 1of the 3 slices. Mathematically, this may be expressed by therelationship X_(rcs), where X denotes an element, and rcs is adimensional index, where each of the indices may take on a value from 1to 3. The specific element X₁₁₃ may be identified as that element at theintersection of row 1, column 1, and slice 3.

From the foregoing, it will be apparent that although the exemplarymatrix of FIG. 14 is a 3×3×3 matrix, the principles of matrix definitionand element formation will hold for matrices with a much greater numberof rows, columns, and slices. In particular, an 8 row, 8 column, 8 slicematrix may still be represented mathematically as X_(rcs), where rc ands may now take on values from 1 to 8. Thus, a 3-dimensional 8×8×8 matrixis able to accommodate identifiers for 512 elements.

Returning now to the method flow diagram of FIG. 13, followingdefinition of an N-dimensional sample matrix, particular blood or plasmadonation samples are mapped to each of the elements defined by thematrix. In an exemplary 3-dimensional 8×8×8 matrix, a sample from eachof 512 individual donations is associated with a matrix element, andidentified by a corresponding, unique X_(rcs) indicator.

Next, an aliquot is taken from each sample, and a multiplicity of minorsub-group pools are formed. Each minor pool comprises the aliquots ofall of the samples (X_(rcs)) in which 1 of the dimensional indices isfixed. In other words, in accordance with the above-described exemplarymatrix, all of the samples (X_(rcs)) which have r=1, regardless of thecolumn or slice value, are formed into a minor pool; likewise for r=2,r=3 . . . r=N; likewise for c=1, regardless of row or slice value, c=2,. . . c=N; likewise for s=1, regardless of row or column value, s=2 . .. s=N. Each minor pool thus represents each row, column, layer, or otherdimensional index, such that if an N-dimensional matrix has beendefined, there will be N-dimensions times the (total number ofsamples)^(1/n) minor pools. For the exemplary 3-dimensional 8×8×8 matrixcontaining 512 samples, there will be 24 minor subgroup pools (8 rowpools, 8 column pools, and 8 layer pools). The creation of minor pools,in accordance with the invention, may be viewed as being similar to themathematical method of reducing a determinant by the method of minors.In like manner, each sample will be understood to be represented in Nminor pools, 1 for each dimension of the matrix.

In addition to forming the minor pools, an aliquot of each sample, or analiquot of each of the minor pools, is combined to form a single masterpool which contains a sample from all of the 512 donations comprisingthe present donation space. After all of the pools are formed, anyremaining samples and the minor pools and master pool may be refrozenand stored until such time as PCR testing is desired.

When PCR testing is desired, a PCR test is first performed on the masterpool which represents an aliquot of each sample comprising the matrix.If the test results for the master pool are negative, there are, atleast to the sensitivity level of the PCR test, no viral positivedonations represented by samples forming the matrix. The blood or plasmadonations which have contributed samples to the matrix may be releasedfor further use. However, if the PCR test of the master pool is positivefor a particular genome marker, a second PCR testing cycle is entered,at 300, in which each of the minor pools are now tested.

In a manner similar to that described above, the major pool sizes chosensuch that the statistical probability of their being more than onepositive sample in the major pool (the 512 samples) is small, preferableless than 1 to 2%. This can be done by evaluating the frequency ofoccurrence of the virus of interest in the general donor population to a98% to 99% confidence level. For example, if it is determined that only1 donor out of a general donor population of 1,000 is contaminated withthe virus of interest to a 98% confidence level, there is a 2%probability of finding more than 1 contaminated donor in the next 1,000donors being evaluated. This assures that the algorithm will, ingeneral, be able to identify the single reactive unit in a pool ofappropriate size within the PCR testing cycle. In accordance with theinvention, given a single positive sample within the matrix, 3 of theminor pools will contain an aliquot of the positive donation, 1 in eachdimension. In the exemplary embodiment (the matrix of 512 samples),there are 8 minor row pools, 8 minor column pools, and 8 minor layerpools. If the master pool tests positive, then 1 row, 1 column, and 1layer pool will test positive during the second PCR testing cycle asshown at 307. The intersection of the row, column, and layer elementindex unambiguously identifies the reactive donation as shown at 309.

As an example, if the reactive sample has been mapped to matrix elementX₁₁₃ the row 1 minor pool will return a positive PCR test result, whilethe row 2, and subsequent row minor pools will test negative. Further,the column 1 minor pool will return a positive test result, while thecolumn 2 and subsequent column pools will test negative. Likewise, thelayer 1 and 2 minor pools will return a negative result, the layer 3pool will test positive, and subsequent layer minor pools will testnegative. The 3 positive minor pools (row 1, column 1, and layer 3) haveonly a single element in common, X₁₁₃. Thus, the positive donation isuniquely identified as represented by the sample mapped to element X₁₁₃.

If there is more than 1 reactive donation in the matrix, the reactivedonations may still be unambiguously identified by the method of theinvention, by no more than 1 additional PCR testing cycle. If it isobserved that more than 1 minor pool of a single dimensional indexreturns a positive test result, while only a single minor poolrepresenting each of the remaining dimensional indices returns apositive test result, the more than 1 positive donations may beunambiguously identified by mathematically evaluating the test resultswithout the need for a third PCR testing cycle.

For example, if a row 1 minor pool, and none other, tests positive; acolumn 1 minor pool, and no other, tests positive; and a layer 1 minorpool and layer 3 minor pool both test positive, there are only twopositive donations comprising the matrix, and they are able to beunambiguously identified as X₁₁₁ and X₁₁₃. No further testing isrequired to arrive at this result.

If, on the other hand, it is observed that multiple minor pools testpositive and their identities indicate changes along 2 dimensionalindices as shown at 310, it will be apparent that there will be z²elements identified as potentially mapped to a positive donation, wherez is the actual number of positive donations comprising the grid.

For example, if the row 1 minor pool, and no other, tests positive; thecolumn 1 and column 3 minor pools test positive; and the layer 1 andlayer 3 minor pools test positive, this suggests that the potentiallypositive candidate elements are X₁₁₁, X₁₁₃, X₁₃₁, and X₁₃₃. Since thereis a multiple in only two of the dimensional indices (column and layer),and for candidate elements, it will be seen that there are only twoactual positive donations comprising the matrix. In this circumstance,all 4 donations may be arbitrarily identified as being positive, anddisposed of or, alternatively, an aliquot may be taken from each of the4 candidate elements and individually PCR tested during a third PCRtesting cycle at 311, in order to uniquely identify which 2 of the 4comprise the actual positive donations.

In like manner, it is mathematically evident that if there are more than2 positive donations in the matrix, and their identifiers vary in morethan 2 dimensions, there will be, at most z^(n) potentially positivecandidate elements identified, where z is the actual number of positivedonations, and where n is the number of dimensions which vary. In thiscircumstance, aliquots are taken of all suspect elements in the matrixand directly tested.

Thus, it can be seen that the method of the invention permitsunambiguous identification of donations which are reactive for aparticular genome marker within a single PCR testing cycle for aninitially positive master pool, within 2 PCR testing cycles for allmatrices which contain a single reactive donation or a multiplicity ofreactive donations which vary along only a single dimensional index, andwithin 3 PCR testing cycles for any other situation.

Accordingly, the practice of the present invention results in the bloodsupply, and blood or plasma products prepared therefrom, beingsubstantially safer by virtue of its being as free as possible fromviral contamination. Advantageously, cost-effective, high-sensitivitytesting is readily performed for the presence of a virus directly. Thus,false indications of virus contamination usually associated withantibody testing during the infectivity window period is avoided.Moreover, the present invention allows cost-effective usehigh-sensitivity tests which are capable of detecting the presence of asingle virus in the test sample, thus helping to insure the freedom ofthe blood supply from incipient viral contamination.

Those skilled in the art will appreciate that the foregoing examples anddescriptions of various preferred embodiments of the present inventionare merely illustrative of the invention as a whole, and that variationsin the shape, size, and number of the various components of the presentinvention, as well as the types of tests implemented, may be made withinthe spirit and scope of the invention. For example, it will be clear toone skilled in the art that the length of the individual and connectedpouches, and therefore their volumetric content, may be progressivelyincreased along the length of the tubing segment. As successive testingsubpools are formed from a smaller and smaller number of samples, thevolume of plasma comprising the pool necessarily decreases. It should beclear that in order to maintain a sufficient volume of plasma in eachsuccessive subpool, successive sample pouches may contain a largervolume in order to accommodate a desired final pool volume. In order toaccommodate pools ranging in size from about 1 ml to about 10 ml, itwill be clear that the volumes of successive sample pouches willincrease from about 0.02 ml to about 0.5 ml, in progressive steps. Inone exemplary embodiment, the pouch volume is 0.02 ml the first pouch tobe used in the largest pool and is 0.2 ml in the final pouch.

It will also be clear to those skilled in the art that the system of theinvention is not limited to the exemplary plasma collection containerand an associated tubing segment. Blood bags or other biological fluidcontainers may be used with equal facility and suitable tubing segmentsmay be attached thereto both prior to fluid collection and after fluidcollection is completed. All that is required is that sample quantitiesof biological fluids be transferred to a tubing segment which is thenformed into pouches in accordance with practice of the invention.

Accordingly, the present invention is not limited to the specificembodiments described herein but, rather, is defined by the scope of theappended claims.

1. A method for identifying viral positive biological fluid donations inthe fewest number of high-sensitivity test cycles, the methodcomprising: (a) providing a multiplicity of biological fluid donations;(b) taking a single aliquot from each of the multiplicity of fluiddonations and combining said aliquots into a single master pool; (c)testing the master pool for viral indication using a high-sensitivityPCR test; (d) providing an indication to a user as to whether the masterpool contains a viral positive sample; (e) where the master pool isfound to contain a viral positive sample, defining an n-dimensionalmatrix, where n is an integer 2 or higher, the matrix comprising amultiplicity of elements, each individual element identified by a uniquematrix notation, the matrix notation comprising at least a separatedimensional index for each dimension of the array; (f) taking a samplefrom each of the multiplicity of biological fluid donations; (g) mappingeach sample to one of said multiplicity of elements of the matrix, eachindividual sample identified by its corresponding element's respectivematrix notation; (h) taking at least n aliquots from each sample; (i)forming from the at least n aliquots of each sample one unique subpoolfor each group of elements having matrix notations with one commondimensional index, each of the subpools containing sample aliquots takenexclusively from samples mapped to elements in which one of thedimensional indices is fixed; (j) testing all of the subpools for viralindication using a high-sensitivity PCR test; (k) determining the fixeddimensional index of each subpool that returns a positive viralindication; (l) combining said fixed dimensional indices to identify asubset of matrix elements that contain a viral positive sample, therebyreducing the number of elements that may contain a viral positivesample; (m) providing an indication to a user as to the identities ofthe subset of matrix elements that may contain a viral positive sample;and (n) where positive indications are provided in more than one subpoolin more than one dimensional index of the matrix then directly testingeach of the potentially positive samples with a high-sensitivity PCRtest to detect the presence of the viral contamination, and producing apositive indication when the sample containing the presence of the viralcontamination is detected.
 2. The method according to claim 1 wherein nis 3, and the matrix is subdivided into rows, columns, and layers,wherein each element is characterized by a matrix notation X_(rcs),where the dimensional indices r, c, and s, respectively, identifyelements comprising a row, a column, and a layer of the matrix.
 3. Themethod according to claim 2, wherein the subpool formation step (f)further comprises: forming r-subpools of aliquots from samplesidentified by a fixed r index but different c and s indices; formingc-subpools of aliquots from samples identified by a fixed c index butdifferent rand s indices; forming s-subpools of aliquots from samplesidentified by a fixed s index but different rand c indices.
 4. Themethod according to claim 3, further comprising the steps of:determining the fixed r index of each r-subpool which returned apositive viral indication; determining the fixed c index of each c whichreturned a positive viral indication; and determining the fixed s indexof each s-subpool which returned a positive viral indication.
 5. Themethod according to claim 4, further comprising the step of substitutingthe fixed r, c, and index of each r-, c-, and s-subpool which returned apositive viral indication for the dimensional indices r, c, and s of thematrix notation, thereby identifying a unique matrix element defined bysaid matrix notation, thus identifying the corresponding viral positivesample.
 6. The method according to claim 1 wherein n is 2, and thematrix is subdivided into rows, and columns, wherein each element ischaracterized by a matrix notation X_(rc) where the dimensional indicesr, and c, respectively, identify elements comprising a row and a columnof the matrix.
 7. The method according to claim 6, wherein the subpoolformation step (f) further comprises: forming r-subpools of aliquotsfrom samples identified by a fixed r index but different c indices;forming c-subpools of aliquots from samples identified by a fixed cindex but different r indices.
 8. The method according to claim 7,further comprising the steps of: determining the fixed r index of eachr-subpool which returned a positive viral indication; and determiningthe fixed c index of each c-subpool which returned a positive viralindication.
 9. The method according to claim 8, further comprising thestep of substituting the fixed r and c index of each r- and c-subpoolwhich returned a positive viral indication for the dimensional indices rand c of the matrix notation, thereby identifying a unique matrixelement defined by said matrix notation, thus identifying thecorresponding viral positive sample.
 10. The method according to claim1, wherein said samples are collected concurrently with the collectionof said multiplicity of biological fluid donations.
 11. The methodaccording to claim 2, wherein said samples are collected concurrentlywith the collection of said multiplicity of biological fluid donations.12. The method according to claim 3, wherein said samples are collectedconcurrently with the collection of said multiplicity of biologicalfluid donations.
 13. The method according to claim 4, wherein saidsamples are collected concurrently with the collection of saidmultiplicity of biological fluid donations.
 14. The method according toclaim 5, wherein said samples are collected concurrently with thecollection of said multiplicity of biological fluid donations.
 15. Themethod according to claim 6, wherein said samples are collectedconcurrently with the collection of said multiplicity of biologicalfluid donations.
 16. The method according to claim 7, wherein saidsamples are collected concurrently with the collection of saidmultiplicity of biological fluid donations.
 17. The method according toclaim 8, wherein said samples are collected concurrently with thecollection of said multiplicity of biological fluid donations.
 18. Themethod according to claim 9, wherein said samples are collectedconcurrently with the collection of said multiplicity of biologicalfluid donations.
 19. The method according to claim 1, wherein saidsamples are collected after the collection of said multiplicity ofbiological fluid donations.
 20. The method according to claim 2, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 21. The method according to claim 3, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 22. The method according to claim 4, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 23. The method according to claim 5, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 24. The method according to claim 6, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 25. The method according to claim 7, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 26. The method according to claim 8, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 27. The method according to claim 9, whereinsaid samples are collected after the collection of said multiplicity ofbiological fluid donations.
 28. The method according to claim 1, whereinsaid multiplicity of donations is more than 500 donations.
 29. Themethod according to claim 2, wherein said multiplicity of donations ismore than 500 donations.
 30. The method according to claim 3, whereinsaid multiplicity of donations is more than 500 donations.
 31. Themethod according to claim 4, wherein said multiplicity of donations ismore than 500 donations.
 32. The method according to claim 5, whereinsaid multiplicity of donations is more than 500 donations.
 33. Themethod according to claim 6, wherein said multiplicity of donations ismore than 500 donations.
 34. The method according to claim 7, whereinsaid multiplicity of donations is more than 500 donations.
 35. Themethod according to claim 8, wherein said multiplicity of donations ismore than 500 donations.
 36. The method according to claim 9, whereinsaid multiplicity of donations is more than 500 donations.
 37. Themethod according to claim 1, wherein the biological fluid is blood. 38.The method according to claim 2, wherein the biological fluid is blood.39. The method according to claim 3, wherein the biological fluid isblood.
 40. The method according to claim 4, wherein the biological fluidis blood.
 41. The method according to claim 5, wherein the biologicalfluid is blood.
 42. The method according to claim 6, wherein thebiological fluid is blood.
 43. The method according to claim 7, whereinthe biological fluid is blood.
 44. The method according to claim 8,wherein the biological fluid is blood.
 45. The method according to claim9, wherein the biological fluid is blood.
 46. The method according toclaim 1, wherein the biological fluid is plasma.
 47. The methodaccording to claim 2, wherein the biological fluid is plasma.
 48. Themethod according to claim 3, wherein the biological fluid is plasma. 49.The method according to claim 4, wherein the biological fluid is plasma.50. The method according to claim 5, wherein the biological fluid isplasma.
 51. The method according to claim 6, wherein the biologicalfluid is plasma.
 52. The method according to claim 7, wherein thebiological fluid is plasma.
 53. The method according to claim 8, whereinthe biological fluid is plasma.
 54. The method according to claim 9,wherein the biological fluid is plasma.
 55. The method according toclaim 1, wherein the viral indication is an indication of a virusselected from the group consisting of HIV and HCV.
 56. The methodaccording to claim 2, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 57. The methodaccording to claim 3, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 58. The methodaccording to claim 4, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 59. The methodaccording to claim 5, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 60. The methodaccording to claim 6, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 61. The methodaccording to claim 7, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 62. The methodaccording to claim 8, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 63. The methodaccording to claim 9, wherein the viral indication is an indication of avirus selected from the group consisting of HIV and HCV.
 64. The methodaccording claim 2, wherein the high-sensitivity test is PCR.
 65. Themethod according claim 3, wherein the high-sensitivity test is PCR. 66.The method according claim 4, wherein the high-sensitivity test is PCR.67. The method according claim 5, wherein the high-sensitivity test isPCR.
 68. The method according to claim 1, wherein, the subset of matrixelements identifies at least one sample as a viral positive sample. 69.The method according to claim 2, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 70. Themethod according to claim 3, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 71. Themethod according to claim 4, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 72. Themethod according to claim 5, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 73. Themethod according to claim 6, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 74. Themethod according to claim 7, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 75. Themethod according to claim 8, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 76. Themethod according to claim 9, wherein, the subset of matrix elementsidentifies at least one sample as a viral positive sample.
 77. Themethod according to claim 1, wherein, the subset of matrix elementsidentifies a single sample as a viral positive sample.
 78. The methodaccording to claim 2, wherein, the subset of matrix elements identifiesa single sample as a viral positive sample.
 79. The method according toclaim 3, wherein, the subset of matrix elements identifies a singlesample as a viral positive sample.
 80. The method according to claim 4,wherein, the subset of matrix elements identifies a single sample as aviral positive sample.
 81. The method according to claim 5, wherein, thesubset of matrix elements identifies a single sample as a viral positivesample.
 82. The method according to claim 6, wherein, the subset ofmatrix elements identifies a single sample as a viral positive sample.83. The method according to claim 7, wherein, the subset of matrixelements identifies a single sample as a viral positive sample.
 84. Themethod according to claim 8, wherein, the subset of matrix elementsidentifies a single sample as a viral positive sample.
 85. The methodaccording to claim 9, wherein, the subset of matrix elements identifiesa single sample as a viral positive sample.
 86. The method according toclaim 1, wherein, the number of indices in at least one dimension of thearray is not equal to the number of indices in the other dimensions ofthe array.
 87. The method according to claim 2, wherein, the number ofindices in at least one dimension of the array is not equal to thenumber of indices in the other dimensions of the array.
 88. The methodaccording to claim 3, wherein, the number of indices in at least onedimension of the array is not equal to the number of indices in theother dimensions of the array.
 89. The method according to claim 4,wherein, the number of indices in at least one dimension of the array isnot equal to the number of indices in the other dimensions of the array.90. The method according to claim 5, wherein, the number of indices inat least one dimension of the array is not equal to the number ofindices in the other dimensions of the array.
 91. The method accordingto claim 6, wherein, the number of indices in at least one dimension ofthe array is not equal to the number of indices in the other dimensionsof the array.
 92. The method according to claim 7, wherein, the numberof indices in at least one dimension of the array is not equal to thenumber of indices in the other dimensions of the array.
 93. The methodaccording to claim 8, wherein, the number of indices in at least onedimension of the array is not equal to the number of indices in theother dimensions of the array.
 94. The method according to claim 9,wherein, the number of indices in at least one dimension of the array isnot equal to the number of indices in the other dimensions of the array.